PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: Beyond germline BRCA mutations

Annals of Oncology

Volumn 27, Issue 5, 2016, Pages 755-757

  Helleday, T ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PROSTATE SPECIFIC ANTIGEN; BRAP PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; UBIQUITIN PROTEIN LIGASE;

ATM GENE; CANCER CHEMOTHERAPY; CANCER RISK; CASTRATION RESISTANT PROSTATE CANCER; DRUG RESPONSE; DRUG SENSITIVITY; EDITORIAL; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GENETIC RISK; GERMLINE MUTATION; HOMOLOGOUS RECOMBINATION; HUMAN; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; DRUG APPROVAL; DRUG EFFECTS; GENETICS; LEGISLATION AND JURISPRUDENCE; MALE; UNITED STATES;

BRCA2 PROTEIN; DRUG APPROVAL; GERM-LINE MUTATION; HUMANS; MALE; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; UBIQUITIN-PROTEIN LIGASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84964791044     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw048     Document Type: Editorial

References (16)

1. Mateo J, Carreira S, Sandhu S et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015; 373: 1697-1708.
2. Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001; 10: 705-713.
3. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)polymerase. Nature 2005; 434: 913-917.
4. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
5. Bryant HE, Helleday T. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res 2006; 34: 1685-1691.
6. McCabe N, Turner NC, Lord CJ et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-8115.
7. Robinson D, Van Allen EM, Wu YM et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015; 161: 1215-1228.
8. Mohindra A, Hays LE, Phillips EN et al. Defects in homologous recombination repair in mismatch-repair-deficient tumour cell lines. Hum Mol Genet 2002; 11: 2189-2200.
9. Birkbak NJ, Wang ZC, Kim JY et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2012; 2: 366-375.
10. Abkevich V, Timms KM, Hennessy BT et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 2012; 107: 1776-1782.
11. Popova T, Manie E, Rieunier G et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 2012; 72: 5454-5462.
12. Helleday T, Eshtad S, Nik-Zainal S. Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet 2014; 15: 585-598.
13. Alexandrov LB, Nik-Zainal S, Siu HC et al. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun 2015; 6: 8683.
14. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415-421.
15. Gottipati P, Vischioni B, Schultz N et al. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 2010; 70: 5389-5398.
16. Mukhopadhyay A, Elattar A, Cerbinskaite A et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 2010; 16: 2344-2351.